Citeline, a Norstella company

The UK is urged to bridge the gap between academia and industry in developing pre-clinical research models, according to the Association of the British Pharmaceutical Industry (ABPI). Innovative models like organ-on-chip and advanced 3D cell cultures can potentially reduce animal testing, but often lack readiness for industry adoption. The ABPI highlights the need for investment and collaboration to enhance model maturity and regulatory acceptance. Other regions, such as the US and EU, have made strides in this area through strategic partnerships and funding, serving as examples for the UK to follow.

Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.

Pink Sheet reporter and editors discuss the likely impacts of Center for Drug Evaluation and Research Director Richard Pazdur’s retirement from the FDA and Tracy Beth Høeg becoming the center’s acting director.

Pink Sheet reporter and editors discuss the likely impacts of Center for Drug Evaluation and Research Director Richard Pazdur’s retirement from the FDA and Tracy Beth Høeg becoming the center’s acting director.

Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US

Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

The UK is urged to bridge the gap between academia and industry in developing pre-clinical research models, according to the Association of the British Pharmaceutical Industry (ABPI). Innovative models like organ-on-chip and advanced 3D cell cultures can potentially reduce animal testing, but often lack readiness for industry adoption. The ABPI highlights the need for investment and collaboration to enhance model maturity and regulatory acceptance. Other regions, such as the US and EU, have made strides in this area through strategic partnerships and funding, serving as examples for the UK to follow.

Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.

Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US

Pink Sheet reporter and editors discuss the likely impacts of Center for Drug Evaluation and Research Director Richard Pazdur’s retirement from the FDA and Tracy Beth Høeg becoming the center’s acting director.

Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.